Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

1285873

USP

Fluticasone propionate

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(6α,11β,16α,17α)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C25H31F3O5S
Numero CAS:
80474-14-2
Peso molecolare:
500.57
Numero MDL:
MFCD00866007
Codice UNSPSC:
41116107
ID PubChem:
329749903
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

fluticasone

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
WMWTYOKRWGGJOA-CENSZEJFSA-N

Informazioni sul gene

human ... NR3C1(2908)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Fluticasone propionate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fluticasone Propionate and Salmeterol Inhalation Aerosol®
  • Fluticasone Propionate and Salmeterol Inhalation Powder
  • Fluticasone Propionate Cream
  • Fluticasone Propionate Inhalation Aerosol®
  • Fluticasone Propionate Inhalation Powder
  • Fluticasone Propionate Lotion

Azioni biochim/fisiol

Fluticasone propionate is a second generation glucocorticoid. Used as an anti-inflammatory agent for asthma. Shown to enhance eosinophil apoptosis in a concentration-dependent manner via the glucocorticoid receptor.

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Note legali

Aerosol is a registered trademark of Cytec Technology Corp.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0000284

Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard

Y0000221

Fluticasone impurity D, European Pharmacopoeia (EP) Reference Standard

1285884

Fluticasone Propionate Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

1285895

Fluticasone Propionate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1285840

Fluticasone Propionate Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

1285910

Fluticasone Propionate Nasal Spray Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001754

Fluticasone propionate for impurity C identification, European Pharmacopoeia (EP) Reference Standard

1285829

Fluticasone propionate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1285818

Fluticasone propionate Related Compound J, United States Pharmacopeia (USP) Reference Standard

PHR1702

Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1844

Fluticasone Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1842

Fluticasone Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1846

Fluticasone Related Compound J, Pharmaceutical Secondary Standard; Certified Reference Material

BP587

Fluticasone propionate, British Pharmacopoeia (BP) Reference Standard

BP588

Fluticasone S-methyl impurity, British Pharmacopoeia (BP) Reference Standard

Y0002249

Fluticasone propionate for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard

PHR2270

Fluticasone Propionate Impurity A, certified reference material, pharmaceutical secondary standard

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H361f,H373

Classi di pericolo

Repr. 2 - STOT RE 2

Organi bersaglio

Endocrine system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 3

1 of 3

vibrant-m

Y0000221

Fluticasone impurity D

USP

USP

1286107

Formoterol fumarate

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

T Welte et al.
International journal of clinical practice, 69(3), 336-349 (2014-11-05)
Chronic obstructive pulmonary disease (COPD) is usually a progressive condition. Undiagnosed early-stage disease, particularly in symptomatic patients, is likely to become more severe with time. Hence, prevention or reduction in disease progression is highly relevant. We evaluated the published data
Wei Liu et al.
Experimental and therapeutic medicine, 8(4), 1313-1317 (2014-09-05)
This study was designed to determine the expression of serum and sputum surfactant protein D (SP-D) in chronic obstructive pulmonary disease (COPD) and its association with treatment response. Sixty-five treatment-naive patients with COPD and 26 normal control subjects were recruited
M Berger et al.
Allergy, 70(3), 257-264 (2014-11-11)
House dust contains mite allergens as well as bacterial products such as lipopolysaccharide (LPS). Asthma exacerbations are associated with the level of exposure to allergens and LPS. LPS can potentiate allergen effects in steroid-naïve patients. Long-acting β2-agonists (LABA) were shown
Brian L Le et al.
Research square (2021-04-07)
The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or
Juliet M Foster et al.
The Journal of allergy and clinical immunology, 134(6), 1260-1268 (2014-07-27)
Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. In a 6-month cluster randomized 2 × 2
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.